Compound: N-PHENYL-1-NAPHTHYLAMINE
SMILES: N(c1c2c(ccc1)cccc2)c3ccccc3
InChIKey: XQVWYOYUZDUNRW-UHFFFAOYSA-N
Synonyms: N-PHENYL-1-NAPHTHYLAMINE, 90-30-2, 1-Anilinonaphthalene, PANA, Antioxidant PAN, N-(1-Naphthyl)aniline, 1-Naphthalenamine, N-phenyl-, Neozone A, Nonox A, Phenylnaphthylamine, Aceto PAN, Phenyl-1-naphthylamine, Vulkanox PAN, 1-Naphthylamine, N-phenyl-, Additin 30, Amoco 32, Antigene PAN, alpha-Naphthylphenylamine, DTXSID2025892, NSC 2622, C.I. 44050, AI3-00528, 5I112077IN, DTXCID605892, 1-N-phenylnaphthylamine, ALGERITE POWDER, RefChem:830919, 201-983-0, N-phenylnaphthalen-1-amine, N-Phenyl-alpha-naphthylamine, 1-naphthylphenylamine, N-Phenyl-1-naphthalenamine, Naphthalen-1-yl-phenyl-amine, N-Fenyl-1-aminonaftalen, N-Phenyl-1-napthyl Amine, N-Phenyl-1-aminonaphthalene, MFCD00003878, 1-(n-phenylamino)naphthalene, .alpha.-Naphthylphenylamine, .alpha.-Phenylnaphthylamine, Phenyl-.alpha.-naphthylamine, MLS002415761, MLS002637634, CHEMBL170408, N-Phenyl-.alpha.-naphthylamine, CHEBI:34876, naphthylphenylamine, NSC-2622, N-1-Naphthylaniline, SMR000112177, Naugard PANA, Nocrac PA, CAS-90-30-2, Nonox AN, N-Phenylnaphthylamine, CCRIS 4701, Fenyl-alpha-naftylamin [Czech], Fenyl-alpha-naftylamin, HSDB 7232, N-Fenyl-1-aminonaftalen [Czech], EINECS 201-983-0, BRN 2211174, Algerite, N-phenyl-N-(1-naphthyl)amine, UNII-5I112077IN, Neozon A, phenyl naphthylamine, 1-phenylaminonaphthalene, 3s0b, n-phenyl-1-napthylamine, 1-Naphthyl phenyl amine, N-phenyl-l-naphthylamine, alpha-naphthyl-phenylamine, Fenyl-.alpha.-naftylamin, Phenyl-alpha-naphthylamine, EC 201-983-0, Naphthalenamine, N-phenyl-, WLN: L66J BMR, SCHEMBL19796, SCHEMBL69928, 4-12-00-03015 (Beilstein Handbook Reference), BIDD:ER0663, orb2564282, SCHEMBL1535641, SCHEMBL7687568, SCHEMBL7751770, SCHEMBL7837393, SCHEMBL9630060, SCHEMBL28419573, SCHEMBL29350230, NSC2622, HMS2270J09, Tox21_202073, Tox21_303075, BDBM50504083, SBB000591, STK182583, AKOS003386028, CS-W010472, HY-W009756, NCGC00091327-01, NCGC00091327-02, NCGC00091327-03, NCGC00091327-04, NCGC00256930-01, NCGC00259622-01, AS-17486, SY010757, 1-NAPHTHYLAMINE, N-PHENYL- [HSDB], DB-000338, NS00010304, P0197, ST50308054, EN300-365758, N-Phenyl-1-naphthylamine, reagent grade, 98%, F229101, SR-01000868875, SR-01000868875-2, Q10859671, InChI=1/C16H13N/c1-2-9-14(10-3-1)17-16-12-6-8-13-7-4-5-11-15(13)16/h1-12,17
Theoretical properties:
molecular_formula: C16H13N
molecular_weight: 219.28 g/mol
exact_mass: 219.104799419 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 1
hydrogen_bond_acceptor_count: 1
rotatable_bond_count: 2
heavy_atom_count: 17
topological_polar_surface_area: 12 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
physical_state: Prisms or needles from alcohol; leaflets from ligroin.
color: Prisms or needles from alcohol; leaflets from ligroin.
odor: Amine-like
boiling_point: 635 °F at 528 mmHg (NTP, 1992)
melting_point: 144 °F (NTP, 1992)
density: Relative density (water = 1): 1.2
solubility: less than 1 mg/mL at 70 °F (NTP, 1992)
flash_point: Flash point > 200 °C
vapor_pressure: 0.00000829 [mmHg]
Descriptions:
pubchem: N-Phenyl-1-naphthylamine is a member of naphthalenes.
chembl: Unnamed Compound is a small molecule listed in the ChEMBL database but has not progressed to an approved clinical phase.
wikipedia: 1-Phenyl-2-propylaminopentane (PPAP), also known as α,N-dipropylphenethylamine (DPPEA) and by the developmental code name MK-306, is an experimental drug related to selegiline which acts as a catecholaminergic activity enhancer (CAE).
PPAP is a CAE and enhances the nerve impulse propagation-mediated release of norepinephrine and dopamine. It produces psychostimulant-like effects in animals. In 2025, it was discovered that PPAP is a potent catecholamine reuptake inhibitor, including of dopamine and to a lesser extent of norepinephrine. The drug is a phenethylamine and amphetamine derivative and was derived via structural modification of selegiline.
PPAP was first described in the literature in 1988 and in the first major paper in 1992. It led to the development of the improved monoaminergic activity enhancer (MAE) benzofuranylpropylaminopentane (BPAP) in 1999. PPAP was a reference compound for studying the MAE system for many years. However, it was superseded by BPAP, which is more potent, selective, and also enhances serotonin. There has been interest in PPAP for potential clinical use in humans, including in the treatment of depression, attention deficit hyperactivity disorder (ADHD), and Alzheimer's disease. It is a controlled substance in Sweden as of 2020.